B3C Newswire10.19.18
Implandata Ophthalmic Products GmbH has appointed Dominick Arena as its board chairman, effective immediately.
Arena is currently an executive advisor for Water Street Healthcare Partners, a strategic investor focused exclusively on the healthcare industry. He brings to the position more than 30 years experience in the medical device industry.
Max Ostermeier, CEO of Implandata stated, "The entire management team is extremely pleased that Dominick is joining our board as chairman. We look forward to closely working with him as we enter into a new and exciting phase with Implandata. Dominick's operational and commercial experience will be of tremendous help as we begin the commercialization of our products. Further, his M&A background will play a key role as we position the company for future strategic partnerships.”
Implandata is a privately held, ISO 13485 certified medical device company, which was founded in 2010 in Hannover, Germany. Implandata develops monitoring technologies for the treatment of glaucoma. With the CE marked EYEMATE system, Implandata has developed the world-wide first solution for continual monitoring of intraocular pressure.
Implandata's EYEMATE eye pressure measurement system consists of an implantable micro sensor, responsible for pressure sensing. It also consists of an external hand held device, which is transferring energy to the micro sensor telemetrically and which is responsible for data read out and storage. A GSM module can be connected with the hand held device for transfer of measurement data to an internet-based database. The eye doctor can be accessed in order to get information about the disease status of the patient. A smartphone-app is in development. It allows the patient to view the pressure profile and to track the pressure history. The app can also be used to communicate with the doctor.
Arena is currently an executive advisor for Water Street Healthcare Partners, a strategic investor focused exclusively on the healthcare industry. He brings to the position more than 30 years experience in the medical device industry.
Max Ostermeier, CEO of Implandata stated, "The entire management team is extremely pleased that Dominick is joining our board as chairman. We look forward to closely working with him as we enter into a new and exciting phase with Implandata. Dominick's operational and commercial experience will be of tremendous help as we begin the commercialization of our products. Further, his M&A background will play a key role as we position the company for future strategic partnerships.”
Implandata is a privately held, ISO 13485 certified medical device company, which was founded in 2010 in Hannover, Germany. Implandata develops monitoring technologies for the treatment of glaucoma. With the CE marked EYEMATE system, Implandata has developed the world-wide first solution for continual monitoring of intraocular pressure.
Implandata's EYEMATE eye pressure measurement system consists of an implantable micro sensor, responsible for pressure sensing. It also consists of an external hand held device, which is transferring energy to the micro sensor telemetrically and which is responsible for data read out and storage. A GSM module can be connected with the hand held device for transfer of measurement data to an internet-based database. The eye doctor can be accessed in order to get information about the disease status of the patient. A smartphone-app is in development. It allows the patient to view the pressure profile and to track the pressure history. The app can also be used to communicate with the doctor.
